http://ideas.eyeconx.net/story.php?title=real-world-trial-of-ranibizumab-raises-no-safety-signals A large trial of ranibizumab (Lucentis, Novartis) for wet age-related macular degeneration (AMD) has shown no new safety signals.Patients received an average of 4 to 6 injections over 12 months and had a visual acuity gain of 7 letters.The first of 4 planned yearly updates of the ongoing LUMINOUS trial were presented here at the 12th EURETINA Congress; it is expected that the final results will be... Mon, 24 Sep 2012 16:47:20 EDT en